A
$ Value
$0
Shares
80,000
Price
$0
Filed
Jul 3
Insider
Name
Davidson Michael H.
Title
—
CIK
0001573785
Roles
Director
Transaction Details
Transaction Date
2025-07-01
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
80,000
Footnotes
The pre-funded warrant has no expiration date. | The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.